We generated MYCN-knockdown retinoblastoma cell models to assess functional effects and define a MYCN-RB signature, as a potential application to identify patients with retinoblastomas driven by oncogenic MYCN activity who could benefit from MYCN-directed treatment. The gene discussed is RB1; the disease is retinoblastoma.